Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

PURPOSE: Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate this activity, we pooled efficacy and safety data from two single-arm phase II studies (NP28761 and NP28673; ClinicalTrials.gov identifiers: NCT01871805 and NCT01801111, respectively) in patients with ALK...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Gadgeel, Shirish M., Shaw, Alice T., Govindan, Ramaswamy, Gandhi, Leena, Socinski, Mark A., Camidge, D. Ross, De Petris, Luigi, Kim, Dong-Wan, Chiappori, Alberto, Moro-Sibilot, Denis L., Duruisseaux, Michael, Crino, Lucio, De Pas, Tommaso, Dansin, Eric, Tessmer, Antje, Yang, James Chih-Hsin, Han, Ji-Youn, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali, Ou, Sai-Hong Ignatius
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2016
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7845943/
https://ncbi.nlm.nih.gov/pubmed/27863201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.68.4639
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items